Comparative efficacy of antibody-drug conjugates and chemotherapy for malignant tumors: a systematic review and meta-analysis.

In terms of safety, although our analysis did not reach statistical significance (P > 0.05), the proportions of patients experiencing any adverse events (96.8% vs. 93.6%), grade 3–5 adverse event (51.7% vs. 51.8%), and serious adverse event (25.3% vs. 22.4%) were similar between ADC therapy and chemotherapy.

also in 111,027 other papers